{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:41:23Z","timestamp":1762004483573,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.urolonc.2012.01.012","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T11:06:57Z","timestamp":1354619217000},"page":"772-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting"],"prefix":"10.1016","volume":"30","author":[{"given":"Andrea B.","family":"Apolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Barton","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.urolonc.2012.01.012_bib1","article-title":"Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase","volume":"29","author":"Feifer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.01.012_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. International collaboration of trialists","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2012.01.012_bib4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2010.09442.x","article-title":"Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: Further evidence to support the use of neoadjuvant chemotherapy","volume":"107","author":"Canter","year":"2011","journal-title":"BJU Int"},{"issue":"Suppl 7","key":"10.1016\/j.urolonc.2012.01.012_bib6","article-title":"Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy?","volume":"29","author":"Dickstein","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-5347(17)38244-7","article-title":"Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification","volume":"145","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2014a homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1590\/S1677-55382007000100005","article-title":"Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer","volume":"33","author":"McLaughlin","year":"2007","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1464-410X.2005.05401.x","article-title":"Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma","volume":"95","author":"Ficarra","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.012_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-5347(01)64487-2","article-title":"Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases","volume":"158","author":"Ghoneim","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1464-410x.2000.00614.x","article-title":"Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis","volume":"85","author":"Leissner","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.01.012_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib14","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","article-title":"A sequential treatment approach to myoinvasive urothelial cancer: A phase II Southwest Oncology Group trial","author":"deVere White","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2012.01.012_bib16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: An overview of the randomized trials. Early breast cancer trialists' collaborative group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2012.01.012_bib17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2004.09.059","article-title":"Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?","volume":"22","author":"Gill","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib18","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib19","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib20","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.urology.2011.10.050","article-title":"Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder","volume":"79","author":"Yeshchina","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.01.012_bib22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/cncr.24106","article-title":"Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series","volume":"115","author":"Weight","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2012.01.012_bib24","article-title":"Prospective, randomized phase III study comparing two intensified regimens (methotrexate\/vinblastine\/doxorubicin hydrochloride\/cisplatin [MVAC] versus gemcitabine\/cisplatin) in patients with inoperable or recurrent urothelial cancer","volume":"29","author":"Bamias","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6602112","article-title":"A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer","volume":"91","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib29","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","article-title":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients","volume":"77","author":"Petrioli","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-5347(17)37318-4","article-title":"The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer","volume":"147","author":"Splinter","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib33","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.1994.12.7.1394","article-title":"Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up","volume":"12","author":"Schultz","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib34","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00347-5","article-title":"Will Rogers and the results of radical cystectomy for invasive bladder cancer","volume":"18","author":"Wishnow","year":"1991","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2012.01.012_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)66440-3","article-title":"Cystectomy for bladder cancer: A contemporary series","volume":"165","author":"Dalbagni","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urology.2008.07.035","article-title":"Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy","volume":"73","author":"Kassouf","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.01.012_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: A high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"issue":"Suppl 5","key":"10.1016\/j.urolonc.2012.01.012_bib43","first-page":"147","article-title":"Adjuvant chemotherapy in locally advanced bladder cancer (PT3\/PN1\u20132,M0): A phase III study","volume":"39","author":"Otto","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-199501000-00019","article-title":"Adjuvant polychemotherapy of non-organ-confined bladder cancer after radical cystectomy revisited: Long-term results of a controlled prospective study and further clinical experience","volume":"153","author":"St\u00f6ckle","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(17)32822-7","article-title":"Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial","volume":"152","author":"Studer","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","article-title":"A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Freiha","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib47","first-page":"279","article-title":"Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer","volume":"8","author":"Skinner","year":"1990","journal-title":"Semin Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib48","first-page":"533","article-title":"Adjuvant chemotherapy in advanced bladder cancer","volume":"303","author":"Bono","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.urolonc.2012.01.012_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5023","article-title":"Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC)","volume":"26","author":"Cognetti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib51","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status","volume":"29","author":"Stadler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib52","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz-Ares","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib53","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.urology.2004.05.003","article-title":"Local recurrence after radical cystectomy for invasive bladder cancer: An analysis of predictive factors","volume":"64","author":"Honma","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.01.012_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1078-1439(96)00050-6","article-title":"Uncertainty and outcome of invasive bladder tumors","volume":"2","author":"Herr","year":"1996","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib55","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.ju.0000067601.29966.4a","article-title":"Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?","volume":"169","author":"Sweeney","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib56","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0022-5347(05)65284-6","article-title":"Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer","volume":"167","author":"Herr","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib57","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/01.ju.0000052721.61645.a3","article-title":"Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base","volume":"169","author":"Konety","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib58","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/cncr.22250","article-title":"Standardization of pelvic lymphadenectomy performed at radical cystectomy: Can we establish a minimum number of lymph nodes that should be removed?","volume":"107","author":"Koppie","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.01.012_bib59","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0022-5347(05)67632-X","article-title":"The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer","volume":"163","author":"Ennis","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005392-199909010-00021","article-title":"A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder","volume":"162","author":"Slaton","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib61","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0022-5347(05)68936-7","article-title":"Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort","volume":"161","author":"Bassi","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jjco\/hye086","article-title":"Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder","volume":"31","author":"Hara","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib63","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/01.ju.0000043639.55877.17","article-title":"Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy","volume":"169","author":"Leissner","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.01.012_bib64","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1200\/JCO.2005.05.516","article-title":"Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy","volume":"23","author":"Lotan","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:02Z","timestamp":1761040682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1078143912000427"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.01.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}